Hemostemix to Present at Life Science Investor Forum

Rhea-AI Summary

Hemostemix (OTCQB: HMTXF), a leading autologous stem cell therapy company, announced that CEO Thomas Smeenk will present at the Life Science Investor Forum on September 18, 2025, at 12:00 p.m. ET. The company's flagship product, VesCell™ (ACP-01), treats various cardiovascular conditions including peripheral arterial disease and chronic limb threatening ischemia.

The company has demonstrated strong clinical credentials with 498 successful treatments and 11 peer-reviewed publications confirming safety and efficacy. Following Florida Senate Bill 1768's passage, Hemostemix can now offer treatments to no-option patients in Florida, marking a significant milestone in commercialization.

Calgary, Alberta--(Newsfile Corp. - September 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, is pleased to announce that Chief Executive Officer Thomas Smeenk will present live at the Life Science Investor Forum on Thursday, September 18, 2025, at 12:00 p.m. ET.

Hemostemix has established itself as the world's #1 autologous stem cell therapy company, backed by:

• 11 peer-reviewed publications demonstrating safety and efficacy,
  
  
• 498 safe treatments completed to date,
  
  
• Proven efficacy in no-option patients with severe angina, ischemic and non-ischemic dilated cardiomyopathy, and related co-morbidities, including congestive heart failure, peripheral arterial disease (PAD), and chronic limb-threatening ischemia (CLTI).

Mr. Smeenk's presentation will highlight the company's unparalleled clinical record and its expanding treatment opportunities. With the recent passage of Florida Senate Bill 1768 (SB 1768), ACP-01 can now be legally offered to no-option patients in Florida—bringing hope and access to those who previously had no therapeutic path forward.

"ACP-01 is not science fiction—it is science fact. With 498 successful treatments, a strong body of peer-reviewed evidence, and commercial pathways open in Florida, Hemostemix is uniquely positioned to lead the global market for autologous stem cell therapy for cardiovascular diseases," said Thomas Smeenk, CEO of Hemostemix.

The Life Science Investor Forum is an interactive online event where institutional and individual investors can meet and ask questions in real time. Attendees are encouraged to log in ahead of the 12:00 p.m. ET presentation start.

Event Details

• Who: Thomas Smeenk, CEO, Hemostemix Inc.
  
  
• What: Live Presentation at Life Science Investor Forum
  
  
• When: Thursday, September 18, 2025 - 12:00 p.m. ET
  
  
• Where: https://www.virtualinvestorconferences.com/wcc/eh/4814904/category/145232/september-18th-life-sciences-virtual-investor-forum

ABOUT HEMOSTEMIX

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell™ (ACP-01). A recent peer-reviewed article in Cells (June 29, 2025) provides the scientific foundation for how ACP-01 and NCP-01 may enhance brain-computer interface performance by reducing inflammation, fostering angiogenesis and synaptic plasticity, potentially extending implant longevity. Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 50% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit www.hemostemix.com.

For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder: EM: tsmeenk@hemostemix.com / PH: 905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to a webinar related to VesCell.Health and hemostemix.com in furtherance of the sales of VesCell™ (ACP-01), and the commercialization of ACP-01 via the sale and financing of compassionate treatments under Florida SB 1768. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/266810

FAQ

When is Hemostemix (HMTXF) presenting at the Life Science Investor Forum?

Hemostemix CEO Thomas Smeenk will present on Thursday, September 18, 2025, at 12:00 p.m. ET.

How many successful treatments has Hemostemix (HMTXF) completed with its VesCell therapy?

Hemostemix has completed 498 safe treatments to date with its VesCell (ACP-01) therapy.

What conditions does Hemostemix's VesCell therapy treat?

VesCell treats peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia.

Where can investors access Hemostemix's Life Science Investor Forum presentation?

Investors can access the presentation through the Virtual Investor Conferences platform at their website.

What recent regulatory development allows Hemostemix to offer treatments in Florida?

The passage of Florida Senate Bill 1768 (SB 1768) now allows Hemostemix to legally offer ACP-01 treatments to no-option patients in Florida.